DECABID
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Dec 1989
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DECABID is an oral extended-release small-molecule tablet approved by Eli Lilly in 1989. The mechanism of action and specific indications are not publicly documented in available data. Without disclosed MOA or indications, clinical positioning cannot be determined.
LOE Approaching
Product approaching loss of exclusivity with low competitive pressure (30/100), signaling potential team downsizing and transition focus.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring and limited career growth trajectory. Roles on this product are typically maintenance-focused rather than growth-oriented, appealing to specialists managing mature portfolio assets.
Brand ManagerProduct Manager
Worked on DECABID at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.